CH0334081137
CH0334081137
CRISPR Therapeutics AG
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 5.16B EUR | 5.27B EUR | 4.59B EUR | 5.03B EUR |
Enterprise Value | 3.3B EUR | 5.76B EUR | 4.95B EUR | 4.89B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -15.27x | -- | -- | -- |
Price to Sales | 385.49x | 479.26x | 4,585.06x | -- |
Price to Book | 2.95x | 3.02x | 2.53x | 2.62x |
EV/Revenue | 246.16x | 524.03x | 4,949.39x | -- |
EV/EBITDA | -6.42x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -4.18% | -7.09% | -9.29% | -6.3% |